BioElectronics Corp. (PINKSHEETS:
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Participants in the study were randomly assigned to one of three groups, the first a control group, the second a group that used ActiPatch, and the third a group that was treated with over-the-counter strength acetaminophen in the form of Extra Strength Tylenol. Each of the group's participants then evaluated their levels of muscle soreness and discomfort 48 hours after vigorous resistance training designed to induce delayed onset muscle soreness. "The results for the pilot section of this study were highly significant with the ActiPatch group scoring its average level of muscle soreness and discomfort at much lower levels compared to either the control group or the acetaminophen treatment group," commented Andrew Whelan, CEO of BioElectronics, Corp. "We believe this is important research especially considering the many health concerns expressed by the U.S. Food and Drug Administration relative to Tylenol, NSAIDs and other over the counter pain medications. We believe ActiPatch and Allay are both safe and highly effective alternative therapies for those who suffer from pain and discomfort. We look forward to reviewing the full study data and submitting it to FDA in support of our current pending 510(K) applications and additional applications we plan to file in the future." The study, which is Institutional Review Board (IRB) supervised and has been registered with the National Institutes of Health, is being conducted by principal investigator Sheena Kong, M.D. The principal investigator holds no financial position in any form in the study's sponsor, BioElectronics Corp., and will receive no financial compensation of any kind for the completion of the study. BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx Devices, HealFast Therapy and the Allay family of inexpensive, disposable drug-free anti-inflammatory devices.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
